Effect of diltiazem on coronary microcirculation and vascular endothelial function in patients with acute coronary syndrome before surgery
10.3969/j.issn.1673-9701.2025.26.013
- VernacularTitle:术前应用地尔硫(卓)对急性冠脉综合征患者冠脉微循环及血管内皮功能的影响
- Author:
Pengjin SU
1
;
Ziqian WANG
;
Xiuquan SUN
;
Xiaoqian LI
;
Limin MENG
Author Information
1. 河北北方学院研究生学院,河北 张家口 075000
- Publication Type:Journal Article
- Keywords:
Diltiazem;
Acute coronary syndrome;
Coronary microcirculation;
Vascular endothelial function
- From:
China Modern Doctor
2025;63(26):51-54
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of diltiazem on coronary microcirculation and vascular endothelial function in patients with acute coronary syndrome(ACS)before surgery.Methods A total of 96 ACS patients admitted to Fengfeng General Hospital of North China Medical and Health Group between October 2023 and October 2024 were selected as subjects.The patients were divided into experimental group(n=48)and control group(n=48)by using a random number table method.The experimental group received slow intravenous infusion of diltiazem dilution before surgery and continued intravenous diltiazem during the procedure,while the control group received normal saline both preoperatively and intraoperatively.During the operation,coronary microcirculation parameters[coronary angiography,myocardial perfusion grading(TIMI),microcirculatory resistance index,intraoperative slow blood flow,and no-reflux status]were monitored.Vascular endothelial indexes(endothelin-1,vascular endothelial growth factor)were detected before and one week after surgery.Cardiovascular adverse events were also observed within six months postoperative.Results Postoperative TIMI myocardial perfusion grading in experimental group was superior to than that in control group,and the incidence of slow blood flow and no reflux during surgery in experimental group were lower than those in control group.The levels of endothelin-1 and vascular endothelial growth factor in experimental group were lower than those in control group,and the incidence of cardiovascular adverse events in experimental group were lower than those in control group,with statistically significant differences(P＜0.05).Conclusion The use of diltiazem before percutaneous coronary intervention in patients with ACS can effectively increase coronary blood flow,improve coronary microcirculation,and protect vascular endothelial function.
